加载中
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
前收盘价
US$1.07
US$0.00 · 0.00%
盘中时间采用ET。市场数据可能有所延迟。
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
日内区间
当前US$1.07
52周区间
当前US$1.07
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
52
多空交织
风险
64
高风险
动量
38
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
日内区间
当前US$1.07
52周区间
当前US$1.07
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4217.2万 USD | 2.67亿 USD | 2.57亿 USD | 2.11亿 USD | 3.27亿 USD |
| 销货成本 | 1773.8万 USD | 1.18亿 USD | 1.59亿 USD | 7008.3万 USD | 5759.1万 USD |
| 毛利 | 2443.4万 USD | 1.49亿 USD | 9825.2万 USD | 1.41亿 USD | 2.69亿 USD |
| 研究与开发 | 1.05亿 USD | 9333.6万 USD | 1.09亿 USD | 1.99亿 USD | 3.63亿 USD |
| 销售、一般及管理费用 | 9900.4万 USD | 1.5亿 USD | 1.86亿 USD | 1.98亿 USD | 1.7亿 USD |
| 营业费用 | 2.04亿 USD | 2.61亿 USD | 3.01亿 USD | 3.98亿 USD | 5.33亿 USD |
| 利息支出 | 900.1万 USD | 2715.8万 USD | 4054.2万 USD | 3247.4万 USD | 2295.9万 USD |
| 折旧和摊销 | 392.4万 USD | 527.6万 USD | 379.1万 USD | 369.9万 USD | 345.4万 USD |
| 营业利润 | −1.8亿 USD | −1.12亿 USD | −2.03亿 USD | −2.57亿 USD | −2.64亿 USD |
| 净利润 | −1.7亿 USD | 2850.7万 USD | −2.38亿 USD | −2.92亿 USD | −2.87亿 USD |
公司数据更新于 2026年10月11日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI533.74万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM355.88万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF241.94万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO101.12万0.01%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA74.96万0.00%218.24亿 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO46.61万0.00%139.17亿 USD0.24%US$356.78+0.94%
iShares Micro-Cap ETFIWC41.23万0.03%13.17亿 USD0.60%US$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ21.99万0.01%26.7亿 USD0.36%US$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
